Panacea to Halt Excessive Blood-Loss
COMPOSITION: Tranexamic Acid IP 500 mg/5 ml
- Tranexamic acid is a synthetic derivative of the amino acid lysine that exerts its antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen molecules.
- Intravenous administration caused reductions relative to placebo of 29-54% in postoperative blood losses in patients undergoing cardiac surgery with cardiopulmonary bypass.
- Statistically significant reductions in postoperative blood losses and transfusion requirements in a number of types of surgery were reported.
- Tranexamic acid was superior to dipyridamole in the reduction of postoperative blood losses.
- Had similar efficacy to aprotinin and potential cost and tolerability advantages over aprotinin.
- Also appears to reduce rates of mortality and urgent surgery in patients with upper gastrointestinal hemorrhage.
- Reduces menstrual blood loss and is a possible alternative to surgery in menorrhagia, and has been used successfully to control bleeding in pregnancy.
- Active thromboembolic disease
- Severe renal failure